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Abstract
To date, no reference standard for therapy for zygomycosis has been established because there are insufﬁcient clinical data with which
to make such a judgement. Knowledge of the species responsible for the infection and its antifungal susceptibility proﬁle has become
increasingly important in the management of patients. Amphotericin B is the most active drug against all the species involved, followed
by posaconazole, whereas voriconazole has no activity. Echinocandins are completely inactive in vitro, but may be an interesting option
when used in combination with other drugs.
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Introduction
In the last few years, the number of cases of zygomycosis
has increased, especially among immunocompromised
patients, although several authors have also reported infec-
tions in patients with unknown underlying conditions [1–3].
The course of the infection is rapidly progressive and poten-
tially fatal, with high rates of mortality and morbidity. No ref-
erence standard for therapy has yet been established.
Therapy usually requires a combination of measures, includ-
ing antifungal treatment, surgical intervention and control of
the underlying risk factors [4]. The agent of choice for treat-
ing this infection is amphotericin B (AmB) [5]. However,
therapy with this drug has produced variable results; toxicity
often occurs and the immune status of the patient plays an
important role in the outcome, both of which highlight the
importance of developing new strategies for treatment. Posa-
conazole has been used as salvage therapy for zygomycosis
and has improved outcome. [6,7]. In addition, echinocandins
have been used in combination therapies, underlining the
potential utility of other antifungals in the treatment of zygo-
mycosis. The low rates of response to these various thera-
pies can be attributed to a range of factors, but knowledge
of the species responsible for the infection and its antifungal
susceptibility proﬁle is of increasing value in the management
of patients.
Unfortunately, identiﬁcation by morphology examination
of macroscopic and microscopic characteristics requires a
high level of expertise. Kontoyiannis et al. [8] reported a
20% discrepancy between identiﬁcation by means of mor-
phology and that achieved by sequencing internal transcribed
spacers. In addition, antifungal susceptibility testing data are
limited and are based on isolates identiﬁed by their morpho-
logical characteristics [5,9,10].
The aim of this article is to review the antifungal suscepti-
bility proﬁle of the Zygomycetes in order to provide
information for the better management and treatment of the
life-threatening infections they cause.
Available Methodologies for Antifungal
Susceptibility Testing in Zygomycetes
Two standardized methods are available for determining the
susceptibility of moulds to antifungal agents. One method is
the CLSI standard ‘Reference Method for Broth Dilution
Antifungal Susceptibility Testing of Filamentous Fungi’
(Approved Standard M38-A) [11]. This document recom-
mends the use of: (i) standard RPMI-1640 broth; (ii) non-
germinated conidial inoculum suspensions of 104 CFU/mL,
and (iii) for Rhizopus spp., incubation at 35 C for 24 h. The
subcommittee on Antifungal Susceptibility Testing (AFST) of
the European Committee for Antimicrobial Susceptibility
Testing (EUCAST) has developed an alternative standard for
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conidia-forming moulds [12]. The differences with the CLSI
methods are: (i) RPMI-1640 is supplemented with glucose to
reach a 2% concentration, and (ii) inoculum size is between
1 · 105 and 5 · 105 CFU/mL. Inoculum preparations are
performed by means of counting spores in a haematocytom-
eter [13–15]. Concordance between these two methods was
studied by Chryssanthou and Cuenca-Estrella [16], who
found a level of agreement of 92.5%.
Antifungal Susceptibility Proﬁle of
Zygomycetes
Table 1 shows a literature review of the antifungal suscepti-
bility proﬁle of Zygomycetes.
Amphotericin B
Of the antifungal treatments available, AmB shows the best
in vitro activity against most of the species responsible for
zygomycosis (Table 1) [9,17,18]. Unfortunately, these species
have a broad range of susceptibilities to this drug [19,20].
Cunninghamella spp. and Rhizopus spp. have higher minimum
inhibitory concentrations (MICs) to AmB, whereas Mucor
spp. and Absidia spp. are subject to greater activity on the
part of the drug (Table 1). The highest number of clinical fail-
ures relate to infections caused by Cunninghamella bertholleti-
ae, which supports the high AmB MICs reported for this
Zygomycete [2,21–25]. However, several series and case
reports describing successful treatment with this drug have
been published [26–37]. A number of retrospective studies
have reported an increase in survival rates when lipid formu-
lations of AmB were used as ﬁrst-line or salvage therapy,
primarily liposomal AmB (L-AmB) [26–33]. As these formula-
tions are more effective and better tolerated, they have
replaced conventional AmB in the treatment of these infec-
tions.
Azole drugs
Azole drugs have a limited in vitro activity against Zygomy-
cetes. However, in vivo studies with animal models have
shown that they can be active against zygomycosis [38,39]. In
addition, posaconazole has been used as salvage therapy with
positive results, constituting a promising alternative for the
treatment of these infections.
Itraconazole
Although many authors have stated that itraconazole is not
a good choice for treatment of zygomycosis, some cases of
infection have been successfully treated with this drug
[40–42]. In vitro results show that itraconazole is more
active against Zygomycetes than voriconazole and that
some strains are inhibited by low concentrations of itraco-
nazole [18,43–45]. In vitro studies with itraconazole have
shown a wide range of MICs (Table 1) [5,18,46]. Singh et al.
[46] determined the itraconazole MICs for 15 strains of
Zygomycetes, ﬁnding that Rhizomucor, Syncephalastrum and
Mycocladus (Absidia) showed lower MICs of itraconazole
(ranges 0.03–2 mg/L), whereas Cunninghamella and Mucor
were more resistant (ranges 0.5 mg/L to >8 mg/L). These
data are in accordance with ﬁndings reported by Dannaoui
et al. [5], where Mycocladus and Rhizomucor were the two
genera that showed lower itraconazole MICs. In addition, in
a murine model of Mycocladus corymbifer infection, itraco-
nazole therapy increased the survival rate of infected ani-
mals [47,48]. Therefore, itraconazole may be useful in some
cases of zygomycosis in which susceptible strains are
involved.
Voriconazole
Voriconazole is not active against Zygomycetes in vitro. All
studies have shown MICs >2 mg/L. In most studies, MICs
>8 mg/L have been reported [5,9,10,18,21,46]. In addition, it
has been shown that patients with leukaemia or bone
marrow transplantation recipients undergoing voriconazole
prophylaxis can develop breakthrough infections caused by
Zygomycetes [8, 49, 50].
Posaconazole
Posaconazole is the ﬁrst drug in the azole drug family
to show a broad spectrum of activity against Zygomycetes.
In vitro studies have shown good activity against these fungi
(MIC50 £1 mg/L) [5,9,10,18]. The species which have shown
higher MICs for this drug are Rhizopus spp. and Cokeromyces
recurvatus, with a geometric mean of >2 mg/L, whereas
Absidia spp. and M. corymbifer are the most susceptible spe-
cies; Saksenaea vasiformis and Rhizomucor spp. also exhibit
low MICs for posaconazole, although few strains have been
tested (Table 1). In addition, experimental models of infec-
tion have proven the in vivo activity of this drug. Among mice
treated with posaconazole, a survival increase occurred in
mice infected with Mucor spp. [51], partial efﬁcacy was seen
in those infected with M. corymbifer, and a dose-dependent
response was found in those infected with Rhizopus micro-
sporus [52]. In addition, similar results have been obtained
with posaconazole and AmB used as prophylaxis in neutro-
penic mice [53].
Two clinical studies have evaluated the efﬁcacy of posaco-
nazole as salvage therapy for zygomycosis. Van Burik et al.
[7] reported a 60% response in 91 patients and Sun et al.
[51] found a 79% response in 24 patients.
72 Clinical Microbiology and Infection, Volume 15, Supplement 5, October 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 5), 71–76
Finally, some case reports of successful treatment of
patients with zygomycosis have also been published [54–56],
highlighting posaconazole as a promising drug for treatment
of these infections.
Echinocandins
Echinocandins have been reported as inactive in vitro against
Zygomycetes [44,46,57]. Caspofungin has been tested against
217 strains [9], all of which were resistant in vitro (MICs
>16 mg/L). Singh et al. [46] found caspofungin to have no activ-
ity in a collection of 15 Zygomycetes (MICs >16 mg/L). Konto-
yiannis et al. [8] also studied the in vitro activity of caspofungin
against 20 Zygomycetes with similar results (MICs >32 mg/L).
However, murine models of zygomycosis [9,58–60] have
shown that echinocandins may enhance the activity of AmB in
the treatment of these infections. Therefore, echinocandins
have potential use when combined with other antifungal drugs.
Terbinaﬁne
Few studies have analysed the activity of terbinaﬁne against
Zygomycetes. Dannaoui et al. [5] tested terbinaﬁne against
36 Zygomycetes isolates, obtaining a wide range of MICs
(Table 1). Terbinaﬁne was active against all isolates of M. cor-
ymbifer and some Rhizopus and Mucor isolates. Interestingly,
R. microsporus was susceptible to the drug, whereas Rhizopus
oryzae was not.
Combination Therapy
The management of these infections is difﬁcult because of the
limited number of drugs active against the causative agents of
zygomycosis. Several studies have analyzed the in vitro activity
of antifungals in combination against Zygomycetes. Dannaoui
et al. [61] tested 35 isolates of Zygomycetes and found
TABLE 1. In vitro data of antifungal susceptibility of Zygomycetes to amphotericin B, itraconazole and posaconazole
Species n References
Amphotericin B mg/L Itraconazole mg/L Posaconazole mg/L
Range MIC50 MIC90 GM Range MIC50 MIC90 GM Range MIC50 MIC90 GM
Rhizopus spp. 15 [5] 0.06–1 0.5 1 0.42 0.25–32 0.5 4 0.87 0.125–1 0.25 0.50 0.27
101 [9] 0.03–0.5 0.25 0.5 0.03 to >8 0.5 4 0.06–4 0.25 1
6 [57] 1–2 1 0.5–2 1
10 [18] 0.06–2 0.125 0.5 0.33 0.25–8 1 8 3.93 0.25–8 1 8 2.73
R. microsporus 12 [9] 0.03–0.5 0.25 0.25 0.25–1 0.5 0.25–2 0.25
1 [9] 0.25 1
1 [61] 0.25 >16
5 [21] 1–2 1 2 8 to >8 >8 >8
R. oryzae 14 [21] 0.25–8 1 4 0.5 to >8 >128 >128
2 [46] 0.03–0.06 0.04 0.25–4 1.41
20 [9] 0.06–0.5 0.25 0.25 0.25–2 0.5 0.03–1 0.25 1
[43] 0.12–0.25 0.25 0.25 0.5–4 1 2
15 [10] 0.5 2 >8 >8 0.5 8
Mucor spp. 6 [5] 0.03–0.25 0.125 0.09 1–32 8 6.96 0.5–2 1 1.15
41 [9] 0.125–4 0.25 0.5 0.25 to >8 0.5 >8 0.06–2 0.5 2
6 [18] 0.06–0.5 0.25 0.25 0.24 0.25–8 1 2 2.18 0.125–8 0.5 1 1.54
M. circinelloides 6 [9] 0.06–0.5 0.25 2 to >8 1–2
1 [21] 0.25 8
3 [46] 0.03 0.03 0.5 to >8 2.82
M. ramosissimus 3 [21] 0.12–0.5 0.25 0.5 1–8 2 8
Absidia spp. 3 [9] 0.25–0.5 0.5–1 0.125
10 [5] 0.06–0.125 0.125 0.125 0.09 0.03–0.125 0.06 0.25 0.08 0.06–0.25 0.06 0.125 0.09
Mycocladus corymbifer 9 [9] 0.25–0.5 0.25 0.125–0.5 0.06–0.25
5 [18] 0.25–0.5 0.25 0.25 0.30 0.03–0.25 0.06 0.25 0.14 0.03–0.25 0.03 0.25 0.13
4 [21] 0.25 to >16 0.50 >16 1 to >8 2 >8
3 [46] 0.03–0.25 0.05 0.125–2 0.62
1 [61] 0.06 0.03
[43] 0.06–0.25 0.25 0.25 0.25–0.5 0.25 0.5
Rhizomucor spp. 3 [5] 0.06 0.09 0.09
5 [9] 0.125–0.25 0.125 0.125–1 0.06–1
R. pusillus 3 [46] 0.125–0.25 0.16 0.03–0.125 0.07
Cunninghamella spp. 13 [9] 0.25–2 1 0.125–4 1 0.06–1 0.5
5 [18] 0.125–2 0.25 0.25 0.55 0.125–2 0.25 0.5 0.60 0.03–1 0.25 1 0.36
C. bertholletiae 1 [5] 2 1 0.5
1 [21] 4 2
2 [46] 0.25–0.5 0.35 1–4 2
Aphophysomyces elegans 6 [9] 0.03–1 0.125 0.03–4 0.125 <0.016–1 0.03
1 [5] 2 0.5 0.5
4 [18] 0.03–1 0.03 0.25 0.33 0.03–8 0.5 2 2.63 0.03–4 0.25 2 1.57
1 [61] 2 0.5
Saksenaea vasiformis 4 [18] 0.125–2 0.125 0.25 0.23 0.015–0.03 0.015 0.03 0.05 0.015–0.25 0.06 0.125 0.11
1 [21] 0.01
Cokeromyces recurvatus 2 [18] 0.125–2 0.125 2 0.31 0.25–8 0.25 8 4.13 0.25–4 0.25 4 2.13
Syncephalastrum racemosum 2 [46] 0.03 0.03 0.03–0.25 0.1
n, number of isolates per species; MIC50, MIC causing inhibition of 50% of isolates; MIC90, MIC causing inhibition of 90% of isolates; GM, geometric mean.
A blank space means no data.
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synergistic effects between terbinaﬁne + AmB and
terbinaﬁne + voriconazole (in 20% and 44% of isolates,
respectively). Gomez-Lopez et al. [62] evaluated the in vitro
combinations of terbinaﬁne with itraconazole or AmB against
17 clinical isolates of Zygomycetes and found that
terbinaﬁne + itraconazole exhibited a synergistic effect in
82% of isolates, especially for R. microsporus, M. corymbifer
and C. bertholletiae, as did terbinaﬁne + AmB in 53% of
isolates.
Animal models have shown that the interaction between
AmB and caspofungin or posaconazole improves survival in
mice, indicating a synergistic effect between these drugs
[59,63]. Sugar and Liu [39] reported a synergistic effect for
the combination of azole drugs and quinolones in mice with
pulmonary mucormycosis.
In addition, caspofungin combined with AmB was more
successful than AmB alone in treating patients with rhino-
orbital-cerebral mucormycosis [60] and this combination was
also used successfully to treat a case of rhinocerebral zygo-
mycosis in a haematological cancer patient [64].
Conclusions
Zygomycetes are a heterogeneous group of fungi with a wide
antifungal susceptibility proﬁle. Amphotericin B is the agent
of choice to treat zygomycosis. However, its toxicity remains
a problem and therefore alternative therapies are needed,
including, for example, lipid formulations of AmB. Posaconaz-
ole is the second most active agent against these fungi and
has shown good results in vitro, in animal models and also in
patients. Combination therapies with azoles or echinocandins
may also represent alternatives to improve the survival of
patients infected with Zygomycetes.
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